Sinus implant

Results: 63



#Item
1Intersect ENT Announces FDA Submission of NOVA Bioabsorbable Steroid Releasing Implant for Patients with Chronic Sinus Disease MENLO PARK, Calif.—Aug. 1, 2016—Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to

Intersect ENT Announces FDA Submission of NOVA Bioabsorbable Steroid Releasing Implant for Patients with Chronic Sinus Disease MENLO PARK, Calif.—Aug. 1, 2016—Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to

Add to Reading List

Source URL: propelopens.com

- Date: 2016-07-29 19:00:51
    2PROPEL® (mometasone furoate implant, 370 µg) Instructions For Use CAREFULLY READ ALL INSTRUCTIONS PRIOR TO USE STERILE: STORAGE:

    PROPEL® (mometasone furoate implant, 370 µg) Instructions For Use CAREFULLY READ ALL INSTRUCTIONS PRIOR TO USE STERILE: STORAGE:

    Add to Reading List

    Source URL: propelopens.com

    Language: English - Date: 2016-04-01 12:43:40
    3Intersect ENT Announces Publication of PROGRESS Study of Steroid Releasing Implant in Patients With Frontal Sinus Disease Results Demonstrate Clinical Benefits of PROPEL mini in Difficult-to-Treat Patient Population MENL

    Intersect ENT Announces Publication of PROGRESS Study of Steroid Releasing Implant in Patients With Frontal Sinus Disease Results Demonstrate Clinical Benefits of PROPEL mini in Difficult-to-Treat Patient Population MENL

    Add to Reading List

    Source URL: propelopens.com

    Language: English - Date: 2016-07-08 12:30:12
    4164 Warburton Avenue • Hawthorne, NJ 07506 • ( • www.pallottarauzman.com  Notes from the Doctors T  o all my family, friends and patients, can you believe it’s been a year already since

    164 Warburton Avenue • Hawthorne, NJ 07506 • ( • www.pallottarauzman.com Notes from the Doctors T o all my family, friends and patients, can you believe it’s been a year already since

    Add to Reading List

    Source URL: www.pallottarauzman.com

    Language: English - Date: 2014-03-09 22:36:27
    5Foto_Armando_Lopes_NYC.indd

    Foto_Armando_Lopes_NYC.indd

    Add to Reading List

    Source URL: www.dental.upenn.edu

    Language: English - Date: 2015-11-16 17:45:14
    6Intersect ENT Announces Completion of Enrollment in RESOLVE II Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis Company Also Announces Publication of Positive Six-Month Results from RESOLVE Clinica

    Intersect ENT Announces Completion of Enrollment in RESOLVE II Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis Company Also Announces Publication of Positive Six-Month Results from RESOLVE Clinica

    Add to Reading List

    Source URL: propelopens.com

    Language: English - Date: 2016-06-01 10:43:20
    7Intersect ENT Recognized for Gender Diversity by Watermark and UC Davis Company Also Recognized in Deloitte’s 2015 Technology Fast 500 MENLO PARK, Calif., November 17, 2015 – Intersect ENT, Inc. (Nasdaq:XENT), a comp

    Intersect ENT Recognized for Gender Diversity by Watermark and UC Davis Company Also Recognized in Deloitte’s 2015 Technology Fast 500 MENLO PARK, Calif., November 17, 2015 – Intersect ENT, Inc. (Nasdaq:XENT), a comp

    Add to Reading List

    Source URL: propelopens.com

    Language: English - Date: 2015-11-17 11:28:47
    8Intersect ENT Announces Data Further Demonstrating Health Economic Value of PROPEL Steroid Releasing Implants Savings Associated with Reduced Post-Operative Interventions Support Use of PROPEL MENLO PARK, Calif., Novembe

    Intersect ENT Announces Data Further Demonstrating Health Economic Value of PROPEL Steroid Releasing Implants Savings Associated with Reduced Post-Operative Interventions Support Use of PROPEL MENLO PARK, Calif., Novembe

    Add to Reading List

    Source URL: propelopens.com

    Language: English - Date: 2015-11-10 10:16:52
    9Intersect ENT Announces Publication of Position Statement from AAO-HNS on Use of Biomaterials Statement Supports Use of PROPEL, the Only FDA-Approved Biomaterial Used to Improve Patient Outcomes in Sinus Procedures Menlo

    Intersect ENT Announces Publication of Position Statement from AAO-HNS on Use of Biomaterials Statement Supports Use of PROPEL, the Only FDA-Approved Biomaterial Used to Improve Patient Outcomes in Sinus Procedures Menlo

    Add to Reading List

    Source URL: propelopens.com

    Language: English - Date: 2015-10-21 16:28:17
    10

    PDF Document

    Add to Reading List

    Source URL: www.top-messe-service.com

    Language: English - Date: 2011-02-24 12:19:27